Source and scope
This summary is bounded to the recommendations, population and decisions covered by Living guidelines for the pharmacological management of rheumatoid arthritis with disease-modifying anti-rheumatic drugs: April 2026 update. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:CRA RA 2026
Source-attributed clinical priorities
- Recognize persistent inflammatory synovitis and refer early; do not wait for radiographic damage or positive serology.
- Use disease-modifying antirheumatic treatment through a rheumatology-led treat-to-target strategy.
- Monitor disease activity, toxicity, vaccination, infection risk, bone health and cardiovascular risk throughout care.
- Persistent objective synovitis warrants urgent rheumatology referral even when rheumatoid factor is negative.
sources for this section:CRA RA 2026
Practical assessment and management workflow
1
Document swollen and tender joints, morning stiffness, function, extra-articular features and symptom duration.
2
Obtain inflammatory markers, blood count, renal and liver tests and serology without delaying referral for clear synovitis.
3
Screen infection, vaccination, pregnancy and comorbidity before disease-modifying therapy.
4
Measure disease activity and function regularly and adjust treatment toward remission or low disease activity.
sources for this section:CRA RA 2026
Safety, red flags and urgent escalation
- A single hot joint with fever requires aspiration and urgent infection management.
- Treat cervical neurologic symptoms in longstanding rheumatoid disease as possible instability.
- Hold or modify immunosuppression during serious infection only through a clear rheumatology or acute-care plan.
sources for this section:CRA RA 2026
Confirm the local pathway before acting
The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:CRA RA 2026
Source and implementation boundary
Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:CRA RA 2026
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- Canadian Rheumatology AssociationLiving guidelines for the pharmacological management of rheumatoid arthritis with disease-modifying anti-rheumatic drugs: April 2026 updateaccessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Canada question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.